MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6 Approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results